Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Zinc supplementation showed limited benefits in improving muscle health and hydration in boys with DMD. Nearly 30% of participants had low zinc levels initially, with slight improvement post ...

Cardiac complications like arrhythmias, heart failure, and myocardial infarction significantly impact mortality rates in patients with comorbidities. The interaction between cardiac issues and ...

Apart from the AATD indication, there are several other candidates like WVE-N531, WVE-003 and WVE-007 in Wave Life Sciences’ pipeline, which are being developed for rare and prevalent diseases ...

Wave is now looking for new partners for this program. Wave also announced good phase 2 results for its Duchenne muscular dystrophy candidate WVE-N531 earlier this year and is developing therapies for ...

The company’s candidate, WVE-N531, a treatment specifically designed for patients with a mutation in exon 53 of the dystrophin gene. It is a type of gene therapy that aims to restore the ...

In other recent news, WAVE Life Sciences has seen a flurry of activity with promising data from its Duchenne muscular dystrophy (DMD) drug candidate, WVE-N531, leading to raised share targets by ...

It is being developed to address AATD-related lung or liver diseases, or both. Wave last month also announced that its exon-skipping oligonucleotide WVE-N531 improved dystrophin expression in patients ...